Affirma Capital to invest in Chinese lozenges manufacturer PE firm to acquire 25.6% stake in Golden Throat Holdings
Translated by Kim So-in 공개 2021-09-07 08:11:05
이 기사는 2021년 09월 07일 08:07 thebell 에 표출된 기사입니다.
Singapore-headquartered private equity (PE) firm Affirma Capital will acquire a controlling stake in Golden Throat Holdings, a leading manufacturer of lozenges in China.Affirma Capital will acquire a 25.6% stake in the Hong Kong-listed company for HK$530 million (about 80 billion won), or HK$2.80 apiece, a 26% premium to Golden Throat's last closing price, accoding to industry sources on Friday. Affirma Capital’s Korean fund and a global fund will finance about 50% of the acquisition cost, respectively.
Founded in 1956, Golden Throat is the largest lozenges manufacturer in China, with a market share of 25%.
The PE firm plans to withdraw the listing of the company from the Hong Kong Stock Exchange and list it on the Chinese stock market to increase its corporate value.
Affirma Capital is preparing to get approval from the Hong Kong Stock Exchange and Hong Kong Securities and Futures Commission and plans to submit its Scheme Document around September 21. The transaction is likely to be completed around November.
Affirma Capital's fifth Korean Fund, which will finance the deal, initially closed at 450 billion won at the end of last year, with final closing expected in October. It has made three investments since its first closing.
Affirma Capital has been spun out of Standard Chartered Bank after a complex three-year process involving over 50 investments across six regions. The firm not only uses each region’s individual funds for investment, backed by local institutional investors, but also capitalizes on a global pool of capital by using its Global Fund series, formed mainly for principal investments. (Reporting by Hee-yeon Han)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- ICTK, 일반청약 경쟁률 1108대1 '증거금 5.4조'
- [Company Watch]인적분할 나선 서진시스템, 신설법인에 ESS사업 배정
- 골리앗에 맞선 이오플로우, '인슐렛' 소송전 청신호
- [Red & Blue]지투파워, 한수원 체코 원전 수주시 납품 기대감
- 공모 시총 3000억 육박한 ICTK, 기관투자가 '웃음꽃'
- [CVC 톺아보기]'카카오' 계열 편입 '기폭제', 그룹 지원 속 폭풍 성장
- 두산건설, '반도체 메가 클러스터' 수혜 단지 분양
- [코스닥 리빌딩 리포트]1000억 CB 공수표 날린 퀀타피아, 공개매각 추진
- 올리패스 잠재 대주주 사내이사로…수익성 확보 총력
- '대유타워 매각' 대유위니아, 새 원매자 찾기 시동